I got my PhD in computer science in 2017 from Imperial College London and after the postdoctoral fellowship at the Flatiron Institute in New York I started my industrial career at Prescient Design. After Prescient’s acquisition by Genentech in 2021 I joined gRED as a Senior Director to lead a group of extraordinarily talented computational biologists and machine learning scientists and engineers focusing on computational protein design.
Nature Communications, 12(1), 1-14.
My group at Prescient focuses on developing novel computational tools for protein design by combining ideas from structural biology and machine learning. Specifically, we are interested in understanding and modeling antibody sequence-structure-function relationships, developing deep learning generative models for robust antibody representation and sequence-based antibody design. In collaboration with internal groups at gRED we aid to deliver machine learning-based software solutions for accelerating engineering of therapeutic antibodies.